Karl Bergman

CEO at Elypta since inception, founded to enable earlier detection of multiple cancers by means of a metabolism-based self-sampled liquid biopsy. Karl also led digitalization efforts as Chief Digital Officer at Sweden’s largest private healthcare provider and served as Principal in Arthur D. Little’s healthcare & life science practice where he spent eight years assisting clients with strategic challenges, M&A and operational efficiency. Karl holds M.Sc. degrees in Bioengineering and Innovation & Entrepreneurship from Chalmers University of Technology and an MBA from University of Cambridge.